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Abstract 
Objectives: Salivary gland tumours (SGTs) are a group of heterogeneous lesions with complex clinico-pathological 
characteristics and distinct biological behaviours. Previous studies have reported geographic variations in site dis-
tribution, incidence and histological types of SGTs. The aim of this study was to describe the demography of SGTs 
seen at a tertiary health centre and compare findings with previous studies. 
Study design: Data on SGTs from archives of the Department of Oral Pathology and the Department of Pathology, 
University College Hospital Ibadan were retrieved. Information about histological types, age, sex and location were 
analyzed using SPSS for Window (version 20.0; SPSS Inc. Chicago, IL). Reactive and tumor-like lesions such as 
sialometaplasia, benign lymphoepithelial lesion, lymphoepithelial cyst, mucocele, mucous extravasation phenome-
non, ranula, and sialosis were excluded from the study.
Results: 413 SGTs consisting of 221 (53.5%) malignant and 192 (46.5%) benign lesions were seen. SGTs occu-
rred more in females (50.6%) than males (49.4%) with a mean age of 43.7 (±16.9) years and peak age in the fifth 
decade of life. The parotid with 171 (41.4%) cases was the commonest site, followed by palate with 89 (21.5%) 
cases, while only 7(1.7%) cases were seen in sublingual gland. Pleomorphic adenoma with 169 (40.9%)  was the 
most frequent SGT followed by adenoid cystic carcinoma with 93 (22.5%) cases which also was the most frequent 
malignant SGT  while only 3 (0.7%) cases of Warthin’s tumour were seen.
Conclusion: This report is one of few that showed a higher occurrence of malignant SGTs compared to their benign 
counterparts. The findings were essentially similar to findings in Africa but showed SGTs to be more common in 
females. The reason(s) for high occurrence of malignant SGTs in minor salivary glands and the rarity of Warthins 
tumour in this study and other African series compared to those from America needs further investigation.
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Introduction 
Salivary gland tumours (SGTs) are a group of hetero-
geneous lesions with complex clinico-pathological cha-
racteristics and distinct biological behaviours (1). SGTs 
are rare and represent less than 3% of all head and neck 
tumours (2) but they are clinically significant because of 
their histological and behavioural diversity. Considera-
ble challenges with management may also arise because 
of their proximity to important head / neck structures 
(3). Due to the diversity of SGTs, histological classifi-
cation was fraught with discrepancies.  These discrepan-
cies have somewhat been resolved by the World Health 
Organization’s (WHO) Histological Classification of 
SGTs established in 1971, first revised in 1991 and then 
2005, thus establishing a reliable standard for diagnosis 
and study (4).
Reports from previous studies show a wide geographic 
variation in the site distribution, incidence and histo-
logical types of SGTs, however, most studies show 
pleomorphic adenoma to be the commonest SGT (1,4-7). 
Although, the most common malignant SGT varies 
from one study to another, either adenoid cystic carci-
noma (ACC) or mucoepidermoid carcinoma (MEC) are 
usually reported as the most common malignant SGTs 
(1,5-6). The parotid gland is the most frequently affected 
site for SGTs, with the submandibular gland and palate 
being other commonly affected sites while the sublingual 
gland is usually the least affected site. Also, reports have 
shown varying ratios of malignant and benign SGTs in 
the different sites, as the parotid gland tend to have a 
higher percentage of benign lesions while the sublingual 
and the minor salivary glands seem to have a higher per-
centage of malignant SGTs (4,6). 
Many factors have been implicated in the development 
of SGTs, among which is low dose radiation and ultra-
violet radiation. Other factors implicated include; occu-
pational exposure to wood and wood dust, alcohol and 
hair dyes in women and Epstein-Barr virus (6). More 
so, an increased incidence of salivary gland neoplasms 
has been reported among patients with breast cancer (6). 
Though many studies have examined the demography of 
SGTs, most of them did not include the extra-oral minor 
salivary glands. The aim of this study was to describe the 
demography of SGTs of the head and neck region seen at 
a tertiary health centre based on WHO 2005 classifica-
tion of SGTs and compare findings with other studies. 
Material and Methods
Archival data of the Department of Oral Pathology and 
the Department of Pathology, University College Hospi-
tal Ibadan spanning 19 years were retrieved. Information 
about SGTs histology, location, patients age and gender 
were analysed using SPSS for Windows (version 20.0; 
SPSS Inc. Chicago, IL). All cases were categorised ac-
cording to the 2005 WHO Organization histological 
classification. Reactive and tumor-like lesions like sia-
lometaplasia, sialosis, benign lymphoepithelial lesion, 
lymphoepithelial cyst, mucous retention and mucous 
extravasation phenomena were excluded from the stu-
dy. Ethical approval for the study was obtained from 
the Oyo State Research Ethical Review Committee (AD 
13/479/435).
Results
A total of 413 SGTs; consisting of 221 (53.5%) malig-
nant and 192 (46.5%) benign lesions were seen within the 
study period. Table 1 shows a summary of the demogra-
phic distribution of SGTs. Generally, SGTs were slightly 
more common in females (50.6%) than males (49.4%). 
The mean age of occurrence was 43.7 (±16.9) years 
with peak age in the fifth decade of life. Table 2 shows 
the various histologic types of SGTs seen. Pleomorphic 
adenoma (PA) was the most frequently seen SGT with 
169 cases representing 40.9% of all SGTs and 88.0% of 
N (%)
Major/mi-
nor/others
N (%)
M:F Mean age(yrs)(±SD) Peak age
Commonest
lesions (%)
All 413 229:124:58 1:1.02 43.7 (±16.9)
  
 5th 
PA (40.9)
ACC (22.5)
MEC (14.8)
Benign 192 (46.5) 145:41:5 1:1.3 38.2 (±15.5) 4th and 5th 
PA (88.0)
Mye (2.6)
BCA (2.1)
Malignant 221 (53.5) 84:83:53 1.2:1 47.9 (±17.0) 5th and 6th 
ACC (42.1)
MEC (27.6)
AdenoCa Nos 
(13.6)
PA= pleomorphic adenoma, ACC=adenoid cystic carcinoma, MEC= mucoepidermoid carcinoma
Mye=myoepithelioma, BCA= basal cell adenoma, AdenoCa Nos= adenocarcinoma not otherwise 
specified, M=male, F=female.
Table 1. Overview of the Demography of SGTs.
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(1), 67.5% (2), 59.7% (4), 70.0% (6) and 55.7% (8). The 
reason for this uncommon finding may be due to the fact 
that our centre is a referral tertiary centre and the ̔more 
severe cases’ of SGTs, which are more likely to be ma-
lignant, will be referred to our centre. The ̔ less severe 
cases’ which are more likely to be benign (especially the 
intraoral lesions) are more likely to be treated at primary 
and secondary health facilities. There is also the possibi-
lity that malignant SGTs are more prevalent than benign 
SGTs in our study environment due to yet to be determi-
ned genetic or environment factors. Another study from 
south-west Nigeria by Ladeinde et al. (9) also reported a 
higher prevalence of malignant SGTs in their study.
The parotid gland with 171 (41.4%) cases was the com-
monest site followed by minor salivary glands (30%), 
the submandibular gland (11.9%) and the sublingual 
gland (1.7%). This was in conformity with all large se-
ries which showed parotid gland to be the commonest 
site of occurrence (2). Otoh et al. (8) and Kolude et al. 
(10) in previous studies from Nigeria reported that 45.6% 
and 46.5% respectively of SGTs occurred in the parotid 
gland. However, this was at variance with the finding of 
Ladeinde et al. (9) which showed minor salivary gland 
as the most common site of occurrence of SGTs. Olivei-
ra et al. (1) and Ito et al. (2) both from Brazil got higher 
percentages of 67.7% and 69.5% respectively. Chidzon-
ga et al. (7) suggested that racial variations may exist in 
the clinico-pathologic distribution of SGTs with African 
cases having less proportion of SGTs in parotid gland 
but more proportion occurring in the submandibular and 
minor salivary glands when compared with white popu-
lations in Europe and America (Table 4). This suggestion 
seems to be supported by this study and may be due to 
the rarity of Warthin’s tumour (which almost exclusively 
occurs in the parotid) in Africans when compared with 
Caucasians (Table 4). This study found only 7 (1.7%) of 
SGTs in the sublingual gland and this supports various 
reports about the rarity of SGTs in the sublingual gland 
as reported by previous authors, though some authors 
found no SGTs in the sublingual gland (1,2,7,11). Satko 
et al. (5), on the other hand, reported that sublingual tu-
mours represented 3.2% of all SGTs in their study.
PA to be the commonest SGT in this study accounting 
for 40.9% of all SGTs and 88.0% of benign SGTs. Pre-
vious studies have all shown PA to be commonest SGT 
(1,4-6,12,13). The incidence of PA has been reported to 
range from between 40.8% to 70.4% (14). ACC was the 
second most common SGT and the most common ma-
lignant SGT which was corroborated by Chidzonga et 
al. (7) from Zimbawe, Ostman et al. (15) from Sweden, 
Satko et al. (5) from Brastislavia and Otoh et al. (8) from 
North-eastern Nigeria. In contrast, Ansari (11) from 
Iran, Ito et al. (2) from Brazil, Al-Khateeb et al. (6) from 
Jordan and Kolude et al. (10) from Nigeria found MEC 
to be the commonest malignant SGT in their studies.
benign SGTs. The mean age of occurrence for malignant 
SGTs was 47.9 (±17.0) years while the mean age was 
38.2 (±15.5) years in benign SGTs. There was a statis-
tically significant difference in the mean ages of malig-
nant SGTs and benign SGTs (p=0.00). Malignant SGTs 
occurred more in males than in females with a male: fe-
male ratio of 1.2:1 while benign SGTs occurred more in 
females than males (male: female ratio= 1:1.3). 
The parotid with 171 (41.4%) cases was the commonest 
site, followed by submandibular and sublingual glands 
with 49 (11.9%) and 7 (1.7%) cases respectively. The 
palate with 89 (21.5%) cases was the commonest site 
of occurrence in the minor salivary glands followed by 
buccal mucosa with 17 (4.1) cases. Table 3 shows the 
site distribution of the most commonly seen SGTs.
Discussion
This study reviewed 413 cases of SGTs and showed 
that malignant SGTs were more common than benign 
SGTs representing 53.5% of all cases. This is at varian-
ce with previous studies that reported benign SGTs as 
commoner than malignant with varying values 78.3% 
Table 2. Histologic types of Salivary gland tumours.
Type of tumour N % (Total) % (benign/
malignant)
BENIGN
Pleomorphic adenoma 169 40.9 88.0
Myoepithelioma 5 1.2 2.6
Basal cell adenoma 4 1.0 2.1
PCL 3 0.7 1.6
Canalicular adenoma 3 0.7 1.6
Ductal papilloma 3 0.7 1.6
Cystadenoma 3 0.7 1.6
Clear cell adenoma 2 0.5 1.0
Total 192 46.5 100
MALIGNANT
Adenoid cystic carcinoma 93 22.5 42.1
Mucoepidermoid carcinoma 61 14.8 27.6
Adeno CA NOS 30 7.3 13.6
PLGA 7 1.7 3.2
Acinic cell carcinoma 6 1.5 2.7
PAC 6 1.5 2.7
CA exPA 5 1.2 2.3
Basal cell adenocarcinoma 3 0.7 1.4
Squamous cell carcinoma 3 0.7 1.4
Salivary duct carcinoma 2 0.5 0.9
Mucinous adenocarcinoma 2 0.5 0.9
Sabaceous adenocarcinoma 1 0.2 0.5
Oncoytic carcinoma 1 0.2 0.5
PCAC 1 0.2 0.5
Total 221 53.5 100
PCL= papillary cystadenoma lymphomatosum, CA exPA= carci-
noma ex pleomorphic adenoma, Adeno CA NOS= adenocarcinoma 
not otherwise specified, PCAC= papillary cystic adenocarcinoma, 
PLGA=polymorphous low grade adenocarcinoma, PAC=papillary 
adenocarcinoma
e221
J Clin Exp Dent. 2013;5(5):e218-22. Salivary gland tumours of head and neck
Histological type Parotid n (%)
Submandibular 
n (%)
Sublingual 
n (%)
Minor (Intraoral) 
n (%)
Minor (Extraoral) 
n (%)
BENIGN
Pleomorphic adenoma 96 (57.1) 31 (18.5) 2 (1.2)
35 (20.9)
Pl, 27 (16.1);  Bc,6 (3.6) 
FOM,1 (0.6); Li,1 (0.6)
4 (2.4)
Ne,2 (1.2);  infr,1 (0.6)
No,1 (0.6)
Myoepithelioma 4 (80.0) 0 (0.0) 0 (0.0) 1 (20.0)Bc, 1 (20.0) 0 (0.0)
Basal cell adenoma 1 (25.0) 2 (50.0) 0 (0.0) 1 (25.0)Pl, 1 (25.0) 0 (0.0)
PCL 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
MALIGNANT
Adenoid cystic carcinoma 20 (21.5) 3 (3.2) 1 (1.1)
49 (52.8)
Pl, 36 (38.7); Bc, 8 (8.6)
Ton, 2 (2.2); Li, 2 (2.2)
Fom, 1 (1.1)
20  (21.5)
Ne, 1(1.1); No, 7(7.5)
Ant ,7 (7.5); Man, 4(4.3)
Tem, 1(1.1)
Mucoepidermoid carcinoma 23 (38.3) 10 (16.4) 0 (0.0)
16 (26.7)
Pl,13(21.3);Bc,1(1.6)
Ton ,2 (3.3)
11  (18.4)
No, 3 (5.0) 
Ant, 1 (1.7);  Sph, 1 (1.7) 
Tons, 1 (1.7) ; Man ,5 (8.2)
Adeno CA NOS 5 (17.2) 1 (3.4) 1 (3.4)
8  (27.5)
Pl, 7 (24.1); Bc, 1(3.4)
14 (48.1)
No, 6 (20.7); Ant, 5(17.2)
Naso, 1 (3.4); Lar, 1 (3.4)
Man, 1 (3.4)
PLGA 0 (0.0) 1 (14.3) 1 (14.3)
3 (57.1)
Pl, 2 (28.6);  Fom, 1 
(14.3) Li, 1 (14.3)
1 (14.3)
Ant, 1 (14.3)
Pl=palate, Bc=buccal mucosa, Fom=floor of mouth, Ton=tongue, Li=lip, Man=mandible, Ne=neck, No=nose, infr=Infrorbital, 
Ant=antrum, Tons=tonsils, Sph=sphenoid, Naso=nasopharynx, Lar=larynx. PLGA=polymorphous low grade adenocarcinoma, Adeno 
CA NOS= adenocarcinoma not otherwise specified, PCL= PCL= Papillary cystadenoma lymphomatosum.
Table 3. Distribution of the most common types of SGTs according to site.
Table 4. Comparison of studies on SGTs.
Author
/year country
Sample 
size
M
(%)
F
(%)
Benign
(%)
Malign
(%)             Site (%) Common SGT types (%)
PG SMG SLG MG PA WT ACC MEC
AMERICAS
Ito et al. (2) 2005 Brazil 496 45.0 55.0 67.5  32.5 67.7 9.5 0.0 22.8 54.2 8.5 7.9 13.5
Oliveira 
et al.(1)  2009 Brazil 599 39.0 61.0 78.3 21.7 68.5 15.5 0.0 14.7 68.4 6.4 6.6 4.8
Velázquez et al. (16) 
2012 Mexico 360 63.9 36.1 67.0 23.0 78.0 20.7 0.3 17.7 65.6 5.5 5.0 4.7
ASIA
Li et al. (4)
2008 China 3461 52.7 47.3 59.8 40.2 61.0 11.0 1.0 21.0 51.3 4.1 7.3 7.5
Al-Khateeb et al. (6) 
2007 Jordan 102 46.0 54.0 70.0 30.0 51.0 21.0 0.0 28.0 54.0 4.0 13.0 8.0
Ansari et al.(11) 2007 Iran 130 40.0 60.0 68.4 31.6 63.0 23.0 0.0 13.8 65.4 0.0 10.0 11.5
AFRICA
Chidzonga et al. (7) 
1995 Zimbabwe 282 44.3 55.7 79.8 20.2 42.9 19.5 0.0 37.6 73.0 0.7 8.9 4.2
Otoh et al. (8) 2005 Nigeria 79 75.0 25.0 55.7 44.3 45.6 10.1 2.5 40.6 44.3 2.5 9.6 10.1
Present study Nigeria 413 49.4 50.6 46.5 53.5 41.4 11.9 1.7 44.0 40.9 0.7 22.5 14.8
M=male, F=female, Malign=malignant, PG=parotid gland, SMG=submandibular gland, SLG=sublingual gland, MG=minor salivary 
gland, PA=pleomorphic adenoma, WT=Warthins tumour, ACC=adenoid cystic carcinoma, MEC=mucoepidermoid carcinoma
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Only 3 (0.7%) cases of Warthin’s tumour were seen in 
this report. There appears to be a geographical variation 
in the prevalence of Warthin’s tumour as reports from 
Brazil (2), Mexico (16), Slovakia (5), and China (4) 
show prevalence of 4.4% to 10.5% while middle east 
(6,11) and African studies (7,8) indicate that it is a rare 
SGT (0 - 2.5% of SGTs). This disparity may be due to 
the strong association of Warthin’s tumour with tobacco 
use and the rarity of the tumour in Africans and Arabs 
may be explained by the relatively less frequency of to-
bacco use in these regions.
In the present study, the age range was 6-98 years, the 
mean age of occurrence was 43.7 years and the peak 
age incidence was in the 5th decade of life which was in 
conformity with previous studies (4,11,17). The mean 
age for malignant SGTs (47.8 years) was significantly 
higher than mean age for benign SGTs (38.8years) and 
peak age was in the fifth and sixth decades for malignant 
SGTs while it was in the third and fourth decades for be-
nign SGTs. These findings in our study are comparable 
to those of Li et al. (4) in China. In contrast, Oliveira et 
al. (1) from a study in Brazil, reported median ages of 55 
and 43 years for malignant and benign SGTS respecti-
vely while their peak age were in the seventh and fourth 
decades respectively.
Previous studies from Africa (7,8,10) showed that SGTs 
were more common in men than in women, which is 
at variance with our finding of 50.6% in females and 
49.4% in males. However, our finding was in conformi-
ty with many studies from other climes which showed 
either almost equal sex distribution (4) or a slight female 
preponderance (1, 5). Also, our finding of a slight female 
preponderance for benign SGTs and a slight male pre-
ponderance for malignant SGTs was in conformity with 
previous studies from China and Brazil (1,4).
To the best of the author’s knowledge, this report on 
SGTs is the largest series from Africa and one of few to 
show a higher prevalence of malignant SGTs. Our fin-
dings were essentially similar in most respects to reports 
from Africa but showed SGTs to be more common in 
females. The reason(s) for the relatively high occurrence 
of SGT in minor salivary glands and the rarity of War-
thins tumour in this study and other African series com-
pared to those from America need further investigation.
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